Attached files

file filename
EX-10.14 - FORM OF RESTRICTED STOCK UNIT NOTICE AND RESTRICTED STOCK UNIT AGREEMENT BETWEEN - ORAMED PHARMACEUTICALS INC.f10k2017ex10-14_oramed.htm
10-K - ANNUAL REPORT - ORAMED PHARMACEUTICALS INC.f10k2017_oramedpharma.htm
EX-32.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2017ex32-1_oramed.htm
EX-31.2 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2017ex31-2_oramed.htm
EX-31.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2017ex31-1_oramed.htm
EX-23.1 - CONSENT OF KESSELMAN & KESSELMAN, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - ORAMED PHARMACEUTICALS INC.f10k2017ex23-1_oramed.htm
EX-10.23 - REPRESENTATIVE FORM OF INDEMNIFICATION AGREEMENTS BETWEEN ORAMED PHARMACEUTICALS - ORAMED PHARMACEUTICALS INC.f10k2017ex10-23_oramed.htm
EX-10.11 - AMENDMENT, DATED JUNE 30, 2017, TO CONSULTING AGREEMENTS BY AND BETWEEN ORAMED L - ORAMED PHARMACEUTICALS INC.f10k2017ex10-11_oramed.htm
EX-3.1 - COMPOSITE COPY OF CERTIFICATE OF INCORPORATION, AS AMENDED AS OF JANUARY 22, 201 - ORAMED PHARMACEUTICALS INC.f10k2017ex3-1_oramed.htm

Exhibit 32.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

 

In connection with the annual report of Oramed Pharmaceuticals Inc., or the Company, on Form 10-K for the period ended August 31, 2017, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Hilla Eisenberg, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:

 

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: November 29, 2017 /s/ Hilla Eisenberg
  Hilla Eisenberg
  Chief Financial Officer